-
公开(公告)号:US20190151310A1
公开(公告)日:2019-05-23
申请号:US16266832
申请日:2019-02-04
IPC分类号: A61K31/496 , A61K47/54 , A61K38/08 , A61K31/702 , A61K47/55 , A61K38/07
CPC分类号: A61K31/496 , A61K31/702 , A61K38/07 , A61K38/08 , A61K47/549 , A61K47/55 , A61K47/557
摘要: Potent modulators of RNA function can be assembled in cellulo by using the cell as a reaction vessel and a disease-causing RNA as a catalyst. When designing small molecule effectors of function, a balance between permeability and potency must be struck. Low molecular weight compounds are more permeable while higher molecular weight compounds are more potent. The advantages of both types of compounds could be synergized if low molecular weight molecules could be transformed into potent, multivalent ligands via a reaction catalyzed by binding to a target in cells expressing a genetic defect. We demonstrate that this approach is indeed viable in cellulo. Small molecule modules with precisely positioned alkyne and azide moieties bind adjacent internal loops in r(CCUG)exp, the causative agent of myotonic dystrophy type 2 (DM2), and are transformed into oligomeric, potent inhibitors of DM2 RNA dysfunction via a 1,3 Huisgen dipolar cycloaddition reaction, a variant of click chemistry. Additionally, we show that this approach is applicable to the r(CUG) repeating RNA that causes myotonic dystrophy type 1 (DM1). The click chemistry approach also allows for FRET sensors to be synthesized on-site by using r(CUG) repeats as a catalyst. Furthermore it is shown that small molecule binding sites in patient-derived cells can be identified by using reactive approaches termed Chem-CLIP and Chem-CLIP-Map. Lastly, it is shown that small molecules that target r(CUG) expansions can be designed to cleave this RNA by appending a small molecule with a nucleic acid cleaving module.
-
公开(公告)号:US10071168B2
公开(公告)日:2018-09-11
申请号:US14815718
申请日:2015-07-31
CPC分类号: A61K47/6803 , A61K47/557 , A61K47/59 , A61K47/60 , A61K47/6849 , A61K47/6883 , A61K47/6889
摘要: In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.
-
公开(公告)号:US20180214566A1
公开(公告)日:2018-08-02
申请号:US15748335
申请日:2016-07-29
申请人: NANOTICS, LLC
发明人: John Dodgson , Louis Hawthorne
CPC分类号: A61K47/642 , A61K9/0092 , A61K9/1676 , A61K9/51 , A61K47/557 , A61K47/665 , A61K47/6923
摘要: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells.
-
公开(公告)号:US20180072784A1
公开(公告)日:2018-03-15
申请号:US15681074
申请日:2017-08-18
申请人: Baxalta GmbH , Baxalta Incorporated
发明人: Michael DOCKAL , Hartmut Ehrlich , Friedrich Scheiflinger , Ulf Reimer , Ulrich Reineke , Thomas Polakowski , Eberhard Schneider
CPC分类号: C07K14/4703 , A61K38/00 , A61K47/551 , A61K47/557 , A61K47/60 , C07K7/08 , C07K14/001 , Y02A50/463
摘要: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
-
公开(公告)号:US09857371B2
公开(公告)日:2018-01-02
申请号:US13889083
申请日:2013-05-07
申请人: New York University
发明人: Jasna Brujic , Lea-Laetitia Pontani
CPC分类号: G01N33/56966 , A61K9/107 , A61K47/24 , A61K47/557 , A61K47/62 , A61K47/6907 , A61K47/6911
摘要: A biomimetic system is provided for use in modeling cell-cell adhesion mechanisms comprising functionalized emulsion droplets. Further, a cell culture medium and a drug delivery system using said biomimetic system are provided.
-
公开(公告)号:US09855340B2
公开(公告)日:2018-01-02
申请号:US14434585
申请日:2013-10-08
申请人: Ascendis Pharma A/S
发明人: Harald Rau , Tobias Voigt , Burkhardt Laufer , Nicola Bisek , Franziska Hahn , Thomas Knappe
IPC分类号: A61K47/48 , C08G83/00 , C08J3/075 , C08G65/332 , A61K31/4188 , C08G69/44 , C08G69/48 , C08G65/333 , C08F2/22
CPC分类号: A61K47/60 , A61K31/4188 , A61K47/557 , A61K47/59 , A61K47/645 , A61K47/6845 , A61K47/6849 , A61K47/6903 , C08F2/22 , C08G65/332 , C08G65/3322 , C08G65/33337 , C08G65/33389 , C08G69/44 , C08G69/48 , C08G83/004 , C08G83/006 , C08G2210/00 , C08J3/075 , C08J2300/202 , C08J2371/02 , C08J2400/202 , C08J2471/02 , C08L2203/02
摘要: The present invention relates to a process for the preparation of a hydrogel and to a hydrogel obtainable by said process. The present invention further relates to a process for the preparation of a hydrogel-spacer conjugate, to a hydrogel-spacer conjugate obtainable by said process, to a process for the preparation of a carrier-linked prodrug and to carrier-linked prodrugs obtainable by said process, in particular to carrier-linked prodrugs that provide for a controlled or sustained release of a drug from a carrier. In addition, the invention relates to the use of the hydrogel for the preparation of a carrier-linked prodrug.
-
公开(公告)号:US20170058051A1
公开(公告)日:2017-03-02
申请号:US15200629
申请日:2016-07-01
发明人: ULRICH BRINKMANN , EIKE HOFFMANN , STEFAN DENGL , KLAUS MAYER
CPC分类号: C07K16/44 , A61K38/45 , A61K47/557 , A61K47/6817 , A61K47/6829 , A61K47/6835 , A61K47/6879 , A61K47/6893 , A61K2039/505 , C07K16/00 , C07K16/3076 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/94 , C12Y204/02036
摘要: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.
摘要翻译: 本文报道了半抗原多肽毒素和抗半抗原抗体的缀合物,其中在用于半抗原缀合的赖氨酸残基之前或之后的半胱氨酸残基之间形成二硫键,并且在CDR2中的半胱氨酸残基 抗体,由此根据Kabat测定CDR2。
-
公开(公告)号:US09476044B2
公开(公告)日:2016-10-25
申请号:US14337710
申请日:2014-07-22
CPC分类号: C12N15/113 , A61K47/549 , A61K47/557 , C07K14/4705 , C07K19/00 , C12N15/111 , C12N2310/14 , C12N2310/351 , C12N2310/3513 , C12N2320/30 , C12N2320/51 , C12N2330/30
摘要: The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.
摘要翻译: 本发明涉及通过RNA干扰(RNAi)介导靶特异性核酸修饰所需的单链(ss)RNA分子的序列和结构特征,例如靶mRNA降解和/或DNA甲基化。
-
公开(公告)号:US20160279248A1
公开(公告)日:2016-09-29
申请号:US15175160
申请日:2016-06-07
申请人: Centrose, LLC
CPC分类号: C07K16/28 , A61K31/704 , A61K31/7052 , A61K47/557 , A61K47/60 , A61K47/6803 , A61K47/6807 , A61K47/6843 , A61K47/6849 , A61K47/6851 , C07K2317/92
摘要: The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
-
公开(公告)号:US09415113B2
公开(公告)日:2016-08-16
申请号:US13510279
申请日:2010-11-17
申请人: Sean D. Monahan , Paul H. Johnson , Michael S. DeClue , Priyadarsi De , Anna S. Gall , Patrick S. Stayton , Allan S. Hoffman , Charbel Diab
发明人: Sean D. Monahan , Paul H. Johnson , Michael S. DeClue , Priyadarsi De , Anna S. Gall , Patrick S. Stayton , Allan S. Hoffman , Charbel Diab
IPC分类号: A61K31/787 , C07D221/02 , A61K47/06 , A61K47/48
CPC分类号: A61K47/48176 , A61K47/551 , A61K47/557 , A61K47/58 , A61K47/62
摘要: Provided herein are monomers incorporating folate or other targeting agent, polymers prepared therefrom, polymers prepared therefrom having a therapeutic agent covalently coupled thereto, as well as micelles and therapeutic compositions thereof.
摘要翻译: 本文提供了含有叶酸盐或其它靶向剂的单体,由其制备的聚合物,由其制备的聚合物,其具有与其共价偶联的治疗剂,以及胶束和其治疗组合物。
-
-
-
-
-
-
-
-
-